 |  |
SINGAPORE, April 23, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore's premier biotech incubator, today announced a strategic partnership designed to accelerate innovation and growth within the biotechnology sector.
Through this partnership, GenScript will provide exclusive preferential rates along with technical guidance from experienced scientists across its extensive range of biotechnology services and products to NSG Bio residents. This initiative empowers startups and biotech firms within the NSG Bio community, facilitating easier access to state-of-the-art technologies and services, thereby enhancing innovation and speeding up the transition from research to commercialization.
Since its founding in 2019, NSG Bio has supported innovators in developing transformative solutions across health, biomedical, agrifood, and industrial biotechnology sectors. The incubator specializes in precision medicine, nucleic acid technologies, AI-driven drug discovery, synthetic biology, and other groundbreaking areas. With Singapore's largest co-working biotech laboratory and office spaces and extensive networks of local and international partners, suppliers, and industry experts, NSG Bio has supported over 50 resident companies, fostering their growth and success.
"We are excited to partner with NSG Bio to bolster Singapore's dynamic biotechnology ecosystem," stated Dr. Janice Jin, President of GenScript Asia Pacific. "By extending preferential pricing and technical expertise to residents of NSG Bio, we aim to foster greater innovation among emerging biotechnology companies, allowing them to allocate more resources toward achieving scientific breakthroughs and market readiness."
"NSG Bio is committed to fostering a thriving and world-class biotechnology ecosystem in Singapore. Our partnership with GenScript represents a significant step forward in enabling our resident companies to access cutting-edge scientific capabilities and industry expertise. By deepening collaboration between leading global service providers and local biotech innovators, we are helping to catalyze impactful scientific advancements and reinforce Singapore's position as a global hub for biomedical innovation," said Ms. Daphne Teo, Chairwoman of the Board & Founder of NSG Bio.
This partnership reflects a mutual commitment by both GenScript and NSG Bio to empowering biotechnology entrepreneurs and developing a vibrant and resilient biotechnology ecosystem.
About GenScript Biotech Corporation
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than 200,000 customers acrossover100 countries and regions.
Learn more here: https://www.genscript.com
About NSG Bio
Founded with a focus on supporting biotech innovation, NSG Bio offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully equipped, certified BSL-2 laboratory and office infrastructure across 70,000 sq ft in the prime location of Biopolis and Science Park in Singapore. By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG Bio ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients.
For more information, visit www.nsgbio.com
CONTACT:
Hasyim Sim
hasyim.sim@nsgbio.com
SINGAPORE, April 23, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore's premier biotech incubator, today announced a strategic partnership designed to accelerate innovation and growth within the biotechnology sector.
Through this partnership, GenScript will provide exclusive preferential rates along with technical guidance from experienced scientists across its extensive range of biotechnology services and products to NSG Bio residents. This initiative empowers startups and biotech firms within the NSG Bio community, facilitating easier access to state-of-the-art technologies and services, thereby enhancing innovation and speeding up the transition from research to commercialization.
Since its founding in 2019, NSG Bio has supported innovators in developing transformative solutions across health, biomedical, agrifood, and industrial biotechnology sectors. The incubator specializes in precision medicine, nucleic acid technologies, AI-driven drug discovery, synthetic biology, and other groundbreaking areas. With Singapore's largest co-working biotech laboratory and office spaces and extensive networks of local and international partners, suppliers, and industry experts, NSG Bio has supported over 50 resident companies, fostering their growth and success.
"We are excited to partner with NSG Bio to bolster Singapore's dynamic biotechnology ecosystem," stated Dr. Janice Jin, President of GenScript Asia Pacific. "By extending preferential pricing and technical expertise to residents of NSG Bio, we aim to foster greater innovation among emerging biotechnology companies, allowing them to allocate more resources toward achieving scientific breakthroughs and market readiness."
"NSG Bio is committed to fostering a thriving and world-class biotechnology ecosystem in Singapore. Our partnership with GenScript represents a significant step forward in enabling our resident companies to access cutting-edge scientific capabilities and industry expertise. By deepening collaboration between leading global service providers and local biotech innovators, we are helping to catalyze impactful scientific advancements and reinforce Singapore's position as a global hub for biomedical innovation," said Ms. Daphne Teo, Chairwoman of the Board & Founder of NSG Bio.
This partnership reflects a mutual commitment by both GenScript and NSG Bio to empowering biotechnology entrepreneurs and developing a vibrant and resilient biotechnology ecosystem.
About GenScript Biotech Corporation
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than 200,000 customers acrossover100 countries and regions.
Learn more here: https://www.genscript.com
About NSG Bio
Founded with a focus on supporting biotech innovation, NSG Bio offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully equipped, certified BSL-2 laboratory and office infrastructure across 70,000 sq ft in the prime location of Biopolis and Science Park in Singapore. By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG Bio ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients.
For more information, visit www.nsgbio.com
CONTACT:
Hasyim Sim
hasyim.sim@nsgbio.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
GenScript Biotech and NSG Bio Form Strategic Partnership to Drive Biotechnology Innovation
LAS VEGAS, Jan. 9, 2026 /PRNewswire/ -- Guide Sensmart (Booth 21740, Central Hall), a global leader in thermal imaging technology, officially launched its next-generation thermal imaging innovation – ApexVision – alongside a series of new products empowered by the technology. This launch represents a systemic leap for the industry from merely "seeing heat" to "seeing with clarity, precision, and intelligence," marking the dawn of a new era defined by Ultra-Clarity.
CES Show Floor Reaction: "Ultra-Clarity" Draws Deep Engagement
At the Guide Sensmart booth, live product demonstrations powered by ApexVision attracted strong attention from industry analysts to global media. Hands-on comparisons—such as maintaining clear imaging details of distant targets and delivering crisp, smear-free imaging of fast-moving objects—earned consistent praise. Many professional visitors noted that this reliable "what-you-see-is-what-you-get" clarity would directly enhance operational efficiency and decision-making confidence.
ApexVision integrating both hardware and software: It combines the high-sensitivity ApexCore S1 detector, the Nexus 1.0 processing platform, and scenario-optimized algorithms. Together, ApexVision successfully overcomes persistent challenges such as low contrast in complex environments, detail loss at long range or high magnification, motion blur on fast-moving objects, and inaccurate detection of minute temperature differences.
From Architecture to Application: A Full Portfolio Empowered
On the CES show floor, Guide Sensmart demonstrated how ApexVision delivers tangible improvements across thermal devices. Thermography tools (e.g. E3S, H6S thermal cameras) leverage the SharpIR 2.0 algorithm to provide stable, accurate temperature measurement in demanding environments, enabling inspectors to pinpoint hidden faults with greater confidence. Outdoor hunting optics (e.g. TD650LS monocular and TN650MS binocular), benefit from Hyper-Light 2.0, allowing users to identify nocturnal wildlife in complete darkness and track fast-moving targets while maintaining clean, sharp images even at 10× zoom.
"The launch of ApexVision marks a milestone where our vertically integrated technology development translates into real value for users," said a Guide Sensmart spokesperson. "It is more than a set of specifications—it delivers the certainty of Ultra-Clarity to every professional user."
The debut of ApexVision at CES 2026 signifies more than a routine product update. By resolving long-standing trade-offs between sensitivity, stability, and environmental robustness, Guide Sensmart is advancing thermal imaging into the Ultra-Clarity Era, building a clearer, safer, and more efficient future.
We are keen to explore partnership of collaboration with you. Know more about Guide Sensmart at https://www.guideir.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ApexVision Debuts at CES 2026: Guide Sensmart Ushers in the Ultra-Clarity Era of Thermal Imaging
